2026 · 3rd Quarter (July 1 - Sep 30)

BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL)

Filed by TARPLIN, DOWNS & YOUNG, LLC.

Open official filing

Source-reported fields

Filing overview

Type: 3rd Quarter - Report
Posted: Oct 20, 2026
Income: $80,000.00
Expenses: Not reported
Registrant: TARPLIN, DOWNS & YOUNG, LLC
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL)
Filing UUID: a1826e17-cac0-4232-ad4c-4d4b374675b7
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

BUD · Budget/Appropriations

H.R. 8646, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 H.R. 9620, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 Issues pertaining to NIH & FDA funding

Literal federal measure citations: H.R. 8646, H.R. 9620

HCR · Health Issues

S. 4612/H.R. 9000 - the SCREEN For T1D Act S. 8270/H.R. 8018 - the ISLET Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to Special Diabetes Program Issues pertaining to FDA modernization

Literal federal measure citations: S. 4612, H.R. 9000, S. 8270, H.R. 8018

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.